Bexarotene: a promising anticancer agent
- 24 September 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 65 (2), 201-205
- https://doi.org/10.1007/s00280-009-1140-4
Abstract
Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-α, -β and -γ and retinoid X receptors (RXR)-α, -β and -γ. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer.Keywords
This publication has 56 references indexed in Scilit:
- Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic OpportunitiesAntioxidants and Redox Signaling, 2009
- Rexinoid-induced Expression of IGFBP-6 Requires RARβ-dependent Permissive Cooperation of Retinoid Receptors and AP-1Published by Elsevier BV ,2009
- UBE1L causes lung cancer growth suppression by targeting cyclin D1Molecular Cancer Therapeutics, 2008
- Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor–Selective RetinoidCancer Prevention Research, 2008
- Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrateJournal of the American Academy of Dermatology, 2008
- Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinomaActa Endocrinologica, 2006
- Bexarotene and Erlotinib for Aerodigestive Tract CancerJournal of Clinical Oncology, 2005
- Clinging to life: cell to matrix adhesion and cell survivalCancer and Metastasis Reviews, 2005
- The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinomaMolecular Cancer Therapeutics, 2005
- A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung CancerClinical Cancer Research, 2004